Literature DB >> 2209825

Acute lymphoblastic leukemia in the elderly.

A Delannoy1, A Ferrant, A Bosly, C Chatelain, C Doyen, P Martiat, J L Michaux, G Sokal.   

Abstract

We report our findings in 18 patients with acute lymphoblastic leukemia (ALL) aged 60 years or older. A preleukemic syndrome was observed in 2 patients. Compared to younger adults with ALL, L3 morphology was unexpectedly frequent (4/16). T-ALL was not observed. Other criteria of poor prognosis (high white blood cell count, CNS involvement, organomegaly, high serum LDH) were similar to those reported in young adults. 12 patients were treated with an OPAL-derived regimen, 4 with the MAV regimen, 1 with vincristine and prednisone, 1 with 6-mercaptopurine. Complete remission was achieved in 8 patients but proved short-lived. 5 patients died in aplasia and 5 failed to achieve remission. Median survival for the whole group was 3 months. ALL in the elderly raises the dilemma of an aggressive disease in patients with poor tolerance to intensive therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209825     DOI: 10.1111/j.1600-0609.1990.tb00424.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Authors:  Mathilde Hunault-Berger; Thibaut Leguay; Xavier Thomas; Ollivier Legrand; Françoise Huguet; Caroline Bonmati; Martine Escoffre-Barbe; Laurence Legros; Pascal Turlure; Patrice Chevallier; Fabrice Larosa; Frederic Garban; Oumedaly Reman; Philippe Rousselot; Nathalie Dhédin; André Delannoy; Marina Lafage-Pochitaloff; Marie Christine Béné; Norbert Ifrah; Hervé Dombret
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Palliative therapies in elderly cancer patients.

Authors:  F Porzsolt; J Zeeh; D Platt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 3.  Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.

Authors:  Philippe Rousselot; André Delannoy
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 4.  Treatment of older patients with acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Treatment of Older Patients with Acute Lymphoblastic Leukaemia.

Authors:  Nicola Gökbuget
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

Review 6.  Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Two "childhood" malignancies in an elderly individual: a case report and discussion.

Authors:  Lohith S Bachegowda; Gayathri Nagaraj; Petros D Grivas; Lingyi Chen; Eugene Choi; Michael Styler
Journal:  Med Oncol       Date:  2009-09-04       Impact factor: 3.064

8.  Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.

Authors:  E Späth-Schwalbe; G Heil; H Heimpel
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

9.  Acute lymphoblastic leukemia in elderly patients: a single institution's experience.

Authors:  Dong-Yeop Shin; Inho Kim; Ki-Hwan Kim; Younak Choi; Seung Hoon Beom; Yaewon Yang; Yoojoo Lim; Eunyoung Lee; June Koo Lee; Ji Yeon Kim; Hyun Kyung Kim; Sung-Soo Yoon; Dong Soon Lee; Seonyang Park; Byoung-Kook Kim
Journal:  Korean J Intern Med       Date:  2011-09-13       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.